Ceryvyn Therapeutics Ltd
OPT
Classement en actions
#31848
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Prix de l'action
$0.00846342
Dernière synchronisation: 2026-07-27
Capitalisation boursière
$11.27M
Changement (1 jour)
0.00%
Changement (1 an)
-99.75%
Pays
AU
Échange Ceryvyn Therapeutics Ltd (OPT)
Catégorie
Healthcare
Revenus pour Ceryvyn Therapeutics Ltd (OPT)
Revenus en Jun 2025 TTM : $146.02K
Selon les derniers rapports financiers de Ceryvyn Therapeutics Ltd, le chiffre d'affaires actuel de l'entreprise (TTM) est de $146.02K. En 2024, l'entreprise a réalisé un chiffre d'affaires de $124.67K une diminution par rapport à le chiffre d'affaires de l'année 2023, qui était de $161.16K. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Ceryvyn Therapeutics Ltd de 2000 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $146.02K | 478.27% |
| 2025 | $25.25K | -79.75% |
| 2024 | $124.67K | -22.65% |
| 2023 | $161.16K | 28.88% |
| 2022 | $125.05K | 35.95% |
| 2021 | $91.98K | -8.63% |
| 2020 | $100.67K | 27.42% |
| 2019 | $79.01K | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | -100.00% |
| 2008 | $13.77K | -15.24% |
| 2007 | $16.24K | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | $10.15K | 19.47% |
| 2004 | $8.50K | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 8,645,674.12% |
US
|
|
| $2.23B | 1,525,749.73% |
US
|
|
| $15.74B | 10,782,430.21% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 4,123,589.23% |
NL
|
